Risk Stratification in Prostate Cancer Patients

EP: 1.Overview of Prostate Cancer

EP: 2.Challenges of PSA as a Diagnostic Biomarker

EP: 3.Role of Biomarker and Genetic Testing in Prostate Cancer Diagnosis

EP: 4.Emerging Serum, Urine, and Tissue Biomarkers in the Clinical Setting

EP: 5.High Risk Populations in the Development of Prostate Cancer

Now Viewing

EP: 6.Risk Stratification in Prostate Cancer Patients

EP: 7.Challenges in Risk Assessment and Biomarkers in Treatment Recommendations

EP: 8.Influences and Challenges of Biomarkers on Treatment Selection

EP: 9.Efficacy of Biomarker Test Results

EP: 10.Biomarker Use in Patients on Active Surveillance

EP: 11.Use of Molecular Biomarkers Tests

EP: 12.Integrating Biomarker Testing Into the Patient Care Journey

EP: 13.AI and the Future of Biomarkers in Prostate Cancer

EP: 14.Current Advancements in Biomarker Research

EP: 15.Unmet Needs and Treatment Gaps in Prostate Cancer

EP: 16.Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer

EP: 17.Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing

EP: 18.Tim Richardson, MD, on genetic testing in the era of targeted therapies

EP: 19.Paul Sieber, MD, on the future of genetic testing in prostate cancer

Video content above is prompted by the following question:

• How do you approach risk stratification in prostate cancer patients, specifically in those newly diagnosed? (Brian Richardson, MD)
  • Do you rely on the Gleason score, specific biomarkers, or a combination?